

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 52942

Title: Clinical observation of apatinib mesylate for the treatment of multiple micrometastases in the brain: report of 2 cases

Reviewer's code: 02446061

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Professor, Research Scientist

Reviewer's country: Mexico

Author's country: China

Manuscript submission date: 2019-12-17

Reviewer chosen by: Jin-Lei Wang

Reviewer accepted review: 2020-02-03 23:25

Reviewer performed review: 2020-02-04 00:22

Review time: 1 Hour

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input checked="" type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input checked="" type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Dear authors: Report is interesting, several points should be edited. a) Introduction and discussion should be edited for adding mechanisms of action (beyond VEGF) b) Discussion is poor. Why the effect in this two cancer types? Previously apatinib had been mentioned active in gastrointestinal types. Could you suggest putative actions for limiting tumor development? c) Why the used posology? If as you sentenced...There is no clear recommendation or guidance for the study of studying the initial dose and or maintenance dose... d) The traditional medicine or other common intervention could be shared for these two patients? e) Some sentences in discussion lack references supporting them.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

BPG Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No